Hormonal
High resistant starch intake improves postprandial insulin and glucose regulation but may increase plasma TMAO levels, a biomarker for cardiovascular disease risk.
If you are insulin resistant, high resistant starch can help blunt blood sugar and insulin spikes after meals. However, be aware that it may also increase TMAO, a marker linked to heart disease risk in some studies. For most people, the metabolic benefits of better blood sugar control outweigh this risk, but those with existing cardiovascular issues should monitor this closely or consult a doctor.
the HRS meals produced significantly lower postprandial insulin and glucose responses... we also found that plasma levels of trimethylamine-N-oxide (TMAO), a biomarker of cardiovascular disease (CVD) risk, were higher following the HRS diet
Why this rating
Clinical measurements of insulin, glucose, and TMAO in a controlled trial.
Source
Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome
Tanja Maier et al. · mBio · 2017
DOI 10.1128/mbio.01343-17
More from this paper
- Consuming high levels of resistant starch (48-66g/day) shifts the gut microbiome composition by increasing the Firmicutes-to-Bacteroidetes ratio and enriching butyrate-producing taxa such as Faecalibacterium prausnitzii, Roseburia, and Ruminococcus.Good
- High resistant starch intake increases fecal butyrate and propionate levels and alters host lipid metabolism pathways, including increased abundance of host lipases and specific fatty acids.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →